Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
184.31
+0.27 (0.15%)
Dec 5, 2025, 4:00 PM EST - Market closed

Company Description

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.

It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services.

The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services.

The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products.

This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies.

It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads.

It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization.

Additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development.

The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International, Inc.
Charles River Laboratories International logo
Country United States
Founded 1947
IPO Date Jun 23, 2000
Industry Diagnostics & Research
Sector Healthcare
Employees 20,100
CEO James Foster

Contact Details

Address:
251 Ballardvale Street
Wilmington, Massachusetts 01887
United States
Phone 781 222 6000
Website criver.com

Stock Details

Ticker Symbol CRL
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001100682
CUSIP Number 159864107
ISIN Number US1598641074
Employer ID 06-1397316
SIC Code 8731

Key Executives

Name Position
James C. Foster J.D. Chairman, President and Chief Executive Officer
Birgit Girshick Corporate Executive Vice President and Chief Operating Officer
Joseph W. LaPlume J.D. Corporate Executive Vice President of Corporate Development and Strategy
Victoria L. Creamer Corporate Executive Vice President and Chief People Officer
Michael Gunnar Knell Interim Chief Financial Officer, Corporate Senior Vice President and Chief Accounting Officer
Prof. Julie Frearson Ph.D. Corporate Senior Vice President and Chief Scientific Officer
Mark Mintz Corporate EVice President, Chief Information Officer and Global Shared Services
Todd Spencer Corporate Vice President of Investor Relations
Matthew L. Daniel J.D. Corporate Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
Amy E. Cianciaruso Corporate Senior Vice President, Chief Communications Officer and Government Relations

Latest SEC Filings

Date Type Title
Dec 3, 2025 8-K Current Report
Nov 17, 2025 8-K Current Report
Nov 14, 2025 SCHEDULE 13G/A Filing
Nov 12, 2025 SCHEDULE 13G/A Filing
Nov 5, 2025 10-Q Quarterly Report
Nov 5, 2025 8-K Current Report
Sep 19, 2025 8-K/A [Amend] Current report
Sep 16, 2025 8-K Current Report
Aug 22, 2025 144 Filing
Aug 18, 2025 144 Filing